Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Abstract: Food intervention to make therapy with pazopanib more patient friendly and affordable (#06) | Floor Lubberman

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Abstract: Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches (#05) | Stefanie Krens

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Abstract: A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment (#07) | Apostolos Papachristos

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Abstract: A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models (#O8)

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Abstract: Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio (#10) | Rhys Jones

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Abstract: The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants (#O9) | Parth Upadhyay

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Abstract: Correlation between nivolumab exposure and treatment outcome in NSCLC (#O1) | Sander Bins

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Targeted agents and monoclonal antibodies | Joseph Ciccolini, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Cytotoxic agents | Markus Jörger, MD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel Verdon

International Workshop on HBV Cure 2018

Rationale for Modulating Adaptive Immunity: Therapeutic Vaccination, Checkpoint Inhibitor and others | Robert Thimme

International Workshop on HBV Cure 2018

Clinical progress of the entry inhibitor Myrcludex B | Stephan Urban

International Workshop on HBV Cure 2018

Rationale for different Virological Targets in HBV | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

International Workshop on HBV Cure 2018

Clinical update on reducing HBV virus and antigen production using RNAi | Bruce Given

International Workshop on HBV Cure 2018

Clinical update, antiviral effect and mode of action of capsid assembly modulators | Jeysen Yogaratnam

International Workshop on HBV Cure 2018

Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy | Andrew Vaillant

International Workshop on HBV Cure 2018

Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates | Richard Colonno

International Workshop on HBV Cure 2018

What is the cure rate with current therapies? | Harry Janssen, MD, PhD

International Workshop on HBV Cure 2018

Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies | Andre Boonstra

International Workshop on HBV Cure 2018

Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MD

International Workshop on HBV Cure 2018